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Antipsychotic medication is a mainstay of treatment for
schizophrenia. Risperidone and olanzapine are popular
choices among the new generation drugs.
Objectives
To determine the clinical effects, safety and cost effective-
ness of risperidone were compared with those of olanza-
pine for treating schizophrenia.
Search Strategy
We searched the Cochrane Schizophrenia Group’s Reg-
ister (September 2005), and references of all identified
studies were inspected for further trials. We also con-
tacted relevant pharmaceutical companies for additional
information.
Selection Criteria
We included all clinical randomized trials comparing
risperidone with olanzapine for schizophrenia and
schizophrenia-like psychoses.
Data Collection and Analysis
We extracted data independently. For homogenous
dichotomous data, we calculated random effects, relative
risk (RR), 95% confidence intervals (CIs), and, where
appropriate, numbers needed to treat/harm (NNT/H)
on an intention-to-treat basis. For continuous data, we
calculated weighted mean differences.
Main Results
We found no difference for the outcome of unchanged or
worse in the short term (n = 548, 2 randomized control tri-
al (RCTs), RR = 1.00, 95% CI = 0.88 to 1.15). One study
favored olanzapine for the outcome of relapse/rehospital-
ization by 12 months (n = 279, 1 RCT, RR = 2.16, 95%
CI = 1.31 to 3.54, NNH = 7, 95% CI = 3 to 25). Most
mental state data showed the 2 drugs to be as effective
as each other (n = 552, 2 RCTs, RR ‘no <20% decrease
Positive and Negative Syndrome Scale by 8 weeks’ 1.00,
95% CI = 0.87 to 1.15) (Figure 1). Both drugs commonly
cause adverse events: 75%given eitherdrug experiencedan
adverse event; 20% experienced anticholinergic symp-
toms; both groups experienced insomnia although it
was more frequent with risperidone (n = 1588, 5 RCTs,
RR = 1.41, 95% CI = 1.15 to 1.72, NNH = 15, 95%
CI = 9 to 41); and about 30% experienced sleepiness
(n = 1713, 6 RCTs, RR = 0.92, 95% CI = 0.79 to 1.07).
People given either drugoften experienced extrapyramidal
symptoms (n = 893, 3RCTs,RR = 1.18, 95%CI = 0.75 to
1.88); 25% of people using risperidone and 18% of people
using olanzapine required medication to alleviate these
symptoms (n = 419, 2 RCTs, RR = 1.76, 95% CI = 1.25
to 2.48, NNH = 8, 95% CI = 4 to 25). People allocated
to risperidone (13%) were less likely to gain more
than 7% of their baseline weight compared with those
given olanzapine (28%), and the weight gain was often
considerable and of quick onset (n = 984, 2 RCTs, RR
gain more than 7% of their baseline weight in the short
term 0.47 95% CI = 0.36 to 0.61, NNH = 7, 95% CI = 6
to 10). Risperidone participants were less likely to leave
the study due to metabolic side effects and weight
gain compared with olanzapine participants (n = 667, 1
RCT, RR = 0.19, 95% CI = 0.08 to 0.45). Patients on
risperidone were more likely to experience abnormal
ejaculation (n = 370, 2 RCTs, RR = 4.36, 95% CI = 1.38
to 13.76, NNH = 20, 95% CI = 6 to 176). Both drugs are
associated with high attrition rates; in the long term, 66%
of those allocated risperidone left the study early
compared with 56% given olanzapine (n = 1440, 5
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RCTs, RR = 1.17, 95% CI = 1.08 to 1.27, NNH = 11,
95% CI = 7 to 23) (Figure 2).
Conclusions
We know very little of the effects of these drugs regarding
service outcomes, general functioning and behaviors, en-
gagement with services, and treatment satisfaction from
randomized trials. In the studies, attrition rates are high
and there appears to be little to differentiate between ris-
peridone and olanzapine except on issues of their dif-
ferent but frequent, unpleasant adverse effects. The full
versionof this review isavailableon theCochraneLibrary.1
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Fig. 1. No specific degree of change in mental state (as defined by Positive and Negative Syndrome Scale total).
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Fig. 2. Leaving the study early—for a variety of reasons.
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